Press "Enter" to skip to content

Why Lexicon Pharma's Stock Is Surging Higher Today

Lexicon Pharmaceuticals (NASDAQ: LXRX) shares are trading sharply higher after the company announced it received FDA regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application submission.

Lexicon is a biopharmaceutical company developing medicines that transform patients’ lives. The company commercializes and develops drugs and drug candidates.

Lexicon’s stock was trading higher by 102% to $7.92 at the time of publciaiton.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *